TABLE 6
FROM:
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease
D Charytan and R E Kuntz
BACK TO ARTICLETable 6. Non-GIIb|[sol]|IIIa oral anti-platelet therapy
| Trial | Intervention | Excluded | Creatinine (mg|[sol]|dl) | Conditions Excluded | Function Reported | Other Conditions Reported |
|---|---|---|---|---|---|---|
| CLARITY-TIMI 2898 | Clopidogrel vs placebo | Y | >2.5 | N | N | Y |
| CLASSICS99 | 3 regimens of plavix|[plus]|ASA | Y | >2.0 | N | N | Y |
| CREDO100 | Clopidogrel vs placebo | Y | >3.0 | N | N | Y |
| CURE101 | Clopidogrel vs placebo | N | NA | N | N | Y |
| HOT102 | ASA vs Placebo|[sol]|vitamin E. vs Placebo | N | N | N | Y | Y |
| Primary Prevention Project103 | ASA vs Placebo|[sol]|vitamin E. vs Placebo | N | NA | N | N | Y |
| Second SYMPHONY42 | ASA vs sibrafiban|[plus]|ASA vs sibrafiban | Y | >1.5 | N | Y | Y |
| STAMI104 | Ticlopidine vs ASA | Y | >1.5 |[times]| normal | N | N | Y |
| STARS105 | ASA vs ASA|[plus]|coumadin vs ASA|[plus]|ticlopidine | N | NA | N | N | Y |
| SYMPHONY43 | ASA vs sibrafiban | Y | >1.5 | N | N | Y |
| Taniuchi et al. 106 | Ticlopidine vs clopidogrel | N | NA | N | S | |
| TIM107 | Triflusal vs ASA | Y | Investigator discretion | N | N | Y |
| TPT108 | ASA vs coumadin vs placebo | Y | Investigator discretion | N | N | D |
| WARIS II109 | ASA vs coumadin vs coumadin|[plus]|ASA | N | NA | N | N | Y |
| Women's Health Study110 | ASA vs placebo | N | NA | N | N | Y |
ASA, aspirin; CrCl, creatinine clearance; D, diabetic patients excluded or percent of patients with diabetes not reported; H, hypertension excluded or percent of patients with hypertension not reported; N, no; NA, not applicable; S, smokers excluded or percent of smokers not reported; Y, yes.
Note: To convert serum creatinine in mg|[sol]|dl to |[mu]|mol|[sol]|l multiply by 88.4.
